Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Anemia Common in ACS Patients, Linked with Higher Mortality

Michael O'Riordan

November 23, 2016

News Daily News

Gender Should Not Factor Into DAPT Choice After PCI

L.A. McKeown

August 19, 2016

Presentation CCVVC 2016

Timing of DAPT Interruption and DES Thrombosis

Presenter: Usman Baber

June 16, 2016

News Conference News SCAI 2016

Risk-Treatment Paradox Unfortunately Alive and Well Among Young Women with ACS

L.A. McKeown

May 13, 2016

News Daily News

一项研究探讨了在ACS患者中使用普拉格雷、氯吡格雷的真实情况

May 12, 2015

News Daily News

Un Estudio Explora el Uso en el ‘Mundo Real’ de Prasugrel vs. Clopidogrel en el Manejo del SCA

May 12, 2015

News Daily News

Study Explores ‘Real-World’ Use of Prasugrel vs Clopidogrel in ACS

May 12, 2015

Presentation

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Presenter: Usman Baber

May 11, 2015

News Daily News

高危急性心梗患者更不可能在出院后接受指南推荐的疗法

Yael L. Maxwell

April 03, 2015

News Daily News

Los Pacientes IAM de Alto Riesgo son Menos Propensos a Seguir Tratamientos Recomendados por las Directrices Tras el Alta Hospitalaria

Yael L. Maxwell

April 03, 2015

Advertisement

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Anemia Common in ACS Patients, Linked with Higher Mortality

Gender Should Not Factor Into DAPT Choice After PCI

Timing of DAPT Interruption and DES Thrombosis

Risk-Treatment Paradox Unfortunately Alive and Well Among Young Women with ACS

一项研究探讨了在ACS患者中使用普拉格雷、氯吡格雷的真实情况

Un Estudio Explora el Uso en el ‘Mundo Real’ de Prasugrel vs. Clopidogrel en el Manejo del SCA

Study Explores ‘Real-World’ Use of Prasugrel vs Clopidogrel in ACS

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

高危急性心梗患者更不可能在出院后接受指南推荐的疗法

Los Pacientes IAM de Alto Riesgo son Menos Propensos a Seguir Tratamientos Recomendados por las Directrices Tras el Alta Hospitalaria

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content